Search

Your search keyword '"Cannizzaro, M"' showing total 9 results
Start Over Author "Cannizzaro, M" Publisher elsevier bv
9 results on '"Cannizzaro, M"'

1. PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT

Author

Magro, B., primary, Calvaruso, V., additional, Petta, S., additional, Cacciola, I., additional, Cabibbo, G., additional, Cartabellotta, F., additional, Di Rosolini, A., additional, Davì, A., additional, Cannavò, M., additional, Russello, M., additional, Di Stefano, M., additional, Scifo, G., additional, Di Lorenzo, F., additional, Prestileo, T., additional, Rocca, L. La, additional, Montineri, A., additional, Fuduli, G., additional, Digiacomo, A., additional, Cannizzaro, M., additional, Madonia, S., additional, Licata, A., additional, Malizia, G., additional, Alaimo, G., additional, Bertino, G., additional, Cacopardo, B., additional, Iacobello, C., additional, Averna, A., additional, Guarneri, L., additional, Scalisi, I., additional, Mazzola, G., additional, Mondello, L., additional, Portelli, V., additional, Squadrito, G., additional, Cammà, C., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2019
Full Text
View/download PDF

2. Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: a prospective analysis in the PITER cohort

Author

Quaranta, M.G., primary, Rosato, S., additional, Ferrigno, L., additional, Amoruso, D.C., additional, Monti, M., additional, Di Stefano, P., additional, Filomia, R., additional, Tamburini, F., additional, Migliorino, G., additional, Zanetto, A., additional, Degasperi, E., additional, Cavalletto, L., additional, Brancaccio, G., additional, Blanc, P., additional, Cannizzaro, M., additional, Castelli, E., additional, Morsica, G., additional, Licata, A., additional, and Kondili, L.A., additional

Published
2019
Full Text
View/download PDF

3. Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort

Author

Calvaruso, V., primary, Petta, S., additional, Cacciola, I., additional, Cabibbo, G., additional, Fabio, C., additional, DI Rosolini, M.A., additional, Davì, A., additional, Cannavò, M.R., additional, Russello, M., additional, Di Stefano, M., additional, Scifo, G., additional, DI Lorenzo, F., additional, Tullio, P., additional, Larocca, L.N., additional, Montineri, A., additional, Fuduli, G., additional, DI Giacomo, A., additional, Cannizzaro, M., additional, Madonia, S., additional, Licata, A., additional, Malizia, G., additional, Alaimo, G., additional, Bertino, G., additional, Cacopardo, B., additional, Iacobello, C., additional, Averna, A., additional, Guarneri, L., additional, Scalisi, I., additional, Mazzola, G., additional, Mondello, L., additional, Vincenzo, P., additional, Squadrito, G., additional, Camma, C., additional, Raimondo, G., additional, Craxi, A., additional, and DI Marco, V., additional

Published
2018
Full Text
View/download PDF

4. Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort

Author

Kondili, L., primary, Quaranta, M.G., additional, Rosato, S., additional, Monti, M., additional, Coco, B., additional, Filomia, R., additional, Biliotti, E., additional, Iannone, A., additional, Zanetto, A., additional, Bruno, S., additional, Giorgini, A., additional, Loi, M., additional, Baragli, F., additional, Baiguera, C., additional, Vinci, M., additional, Eleonora, C., additional, Ciaccio, A., additional, Corsini, R., additional, D’ambrosio, R., additional, Labanca, S., additional, Dallio, M., additional, Orlandini, A., additional, Ciancio, A., additional, Buonomo, A.R., additional, Guarnieri, V., additional, Cossiga, V., additional, Masarone, M., additional, Ieluzzi, D., additional, Cannizzaro, M., additional, Soria, A., additional, Siciliano, M., additional, Amoruso, D.C., additional, Brancaccio, G., additional, Weimer, L.E., additional, Ferrigno, L., additional, Tosti, M.E., additional, Estes, C., additional, Razavi, H., additional, and Calvaruso, V., additional

Published
2018
Full Text
View/download PDF

5. Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort

Author

Madonia, S., primary, Calvaruso, V., additional, Filomia, R., additional, Cannavò, M.R., additional, Di Stefano, M., additional, Russello, M., additional, Davì, A., additional, Scifo, G., additional, Volpes, R., additional, Montineri, A., additional, Ficalora, R., additional, Malizia, G., additional, Digiacomo, A., additional, Bertino, G., additional, Alaimo, G., additional, Licata, A., additional, Cacopardo, B., additional, Averna, A., additional, Guarneri, L., additional, Scalisi, I., additional, Colletti, P., additional, Cartabellotta, F., additional, Savalli, F., additional, Cannizzaro, M., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2017
Full Text
View/download PDF

9. Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: a prospective analysis in the PITER cohort

Author

Gianluca Brancaccio, Pierluigi Blanc, Giulia Morsica, Monica Monti, Elisabetta Degasperi, Anna Licata, M. Cannizzaro, Luisa Cavalletto, D.C. Amoruso, Roberto Filomia, F. Tamburini, Luigina Ferrigno, Guglielmo Migliorino, Alberto Zanetto, P. Di Stefano, Stefano Rosato, M.G. Quaranta, Loreta A. Kondili, E. Castelli, Quaranta, M.G., Rosato, S., Ferrigno, L., Amoruso, D.C., Monti, M., Di Stefano, P., Filomia, R., Tamburini, F., Migliorino, G., Zanetto, A., Degasperi, E., Cavalletto, L., Brancaccio, G., Blanc, P., Cannizzaro, M., Castelli, E., Morsica, G., Licata, A., and Kondili, L.A.

Subjects
medicine.medical_specialty, Hepatology, business.industry, Drug-drug interaction, Gastroenterology, elbasvir grazoprevir efficacy, drug-drug interaction, Hepatitic HCV, Piter cohort, Real life data, Viral infection, Prospective analysis, Chronic hepatitis, Internal medicine, Cohort, medicine, Elbasvir, Grazoprevir, In patient, business
Abstract

Introduction: In a previous study, based on PITER cohort data, it was reported that of patients, undergoing direct acting antiviral (DAA) therapy, 30%-44%, are at risk of potential drug-drug interactions (DDI). Aim: We aimed to evaluate the prospective profile of elbasvir/grazoprevir (EBR/GZR) efficacy and safety combined with real life comedication profile. Method: Data from 312 patients (mean age 63 ± 10 years; 44% male, 90% of genotype 1.85% fibrosis stage ≤ F3, 15% with child A cirrhosis), enrolled in PITER by 15 clinical centers and treated with EBR/GZR, with at least three months of follow up after the end of treatment, were evaluated. Comedication profiles (no changes, drugs interrupted, or modified as posology, or those added) were evaluated and the potential DDI were assigned according to HepC Drug Interactions. Results: The SVR12 was reached in 299 (96%) patients. Gender, age, fibrosis stage, previous interferon therapy, diabetes and fatty liver were not related to failure by logistic regression analysis. Of 312 treated patients, 187 (60%) had at least one comorbidity (median: 2 range: 1–6 comorbidities). Follow up data on comedications used were available in 182 patients (21% have taken 1 drug, 24% two drugs, and the remaining 55% from 3–10 drugs). Of 328 comedications used during the DAA therapy, 3% were modified in posology, 2% were interrupted and 3% were new drugs added. None of changes was due to potential DDI. None but statins (in 2% of patients) were reported to require monitoring by HepC Drug Interactions. EBR/GZR was well tolerated. An increase in ALT levels (lower than 3 times of normal levels), were observed in 12 (4%) patients during the DAA therapy. Conclusion: EBR/GZR demonstrated high cure rates and a good safety profile. No drug-drug interactions were recorded in this cohort of treated patients with different comorbidities and comedications used.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results